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Efficacy parameters were based on clinical trials: Jarnerot 2005, Sands 2001, 
Lichtiger 1994 and D'Haens 2001. Twelve-month time horizon was developed. 
Cost data specific for the Polish health care system was based on retrospective 
medical record review of patients with ulcerative colitis. Resource use associated 
with the surgery was based on clinical expert opinion. The unit costs of 
treatment were derived from Polish official tariff lists for health care services 
paid by public payer. Average body weight of the patient (60 kg) was based on 
data from registry of patients with Crohn’s disease, assuming the similar nature 
of the disease. RESULTS: Infliximab was associated with a gain of 0.21 quality 
adjusted life years (QALYs) compared with colectomy. Additional costs 
associated with the biological treatment were estimated at 14,793 PLN. 
Incremental cost-utility ratio was estimated at 69,984 PLN/QALY for infliximab 
compared with colectomy. The sensitivity analysis showed a relative consistency 
of results. CONCLUSIONS: The estimated cost per QALY is much below official 
threshold (99,543 PLN/QALY) which indicates that treatment with infliximab is 
cost effective compared with surgical treatment in Polish conditions.  
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OBJECTIVES: Compare the cost-per-remission of adalimumab (ADA) to 
infliximab (IFX) for the treatment of moderately to severely active ulcerative 
colitis (UC) in the Brazilian public health care system (SUS). METHODS: 
Treatment costs considered drug acquisition costs from a public payer 
perspective in Brazil considering an average patient of 80 kg. The cost/vial of IFX 
and ADA were defined by the latest government acquisitions, as published in the 
official website comprasnet.gov.br. The time horizon was defined at 8, 52 and 54 
weeks of treatment. The recommended dose and dosing intervals were 
according to label of each drug. The nnt was calculated based on the clinical 
remission data gathered at week 8 and week 52/54 from the published phase III 
clinical trials of ADA and IFX, ULTRA-2 and ACT I respectively. (Rutgeerts P 2005; 
Sandborn WJ 2012). RESULTS: At week 8, IFX has a treatment cost of R$ 13.652 
with a cost-per-NNT for clinical remission of R$ 54.610 (bio-naive and all 
patients), compared to ADA with a treatment cost of R$ 8.284 and a cost-per-NNT 
for clinical remission of R$ 115.983/patient and R$ 82.845/bio-naive patient. At 
week 52/54, IFX has a treatment cost of R$ 36.406 compared to ADA with R$ 
31.067/R$ R$ 32.102 per patient. Considering the cost-per-NNT for clinical 
remission at week 52/54, ADA has an average cost of R$ 341.735 compared to IFX 
with a cost-per-NNT for clinical remission of R$ 182.032 at week 52/54. 
Considering bio-naive patients, IFX remains with a cost-per-NNT for clinical 
remission of R$ 182.032 compared to ADA with R$ 310.668/R$ 341.735 at week 
52/54. CONCLUSIONS: IFX has a lower number needed to treat and a lower cost-
per-NNT to achieve clinical remission at both week 8 week 52/54 compared with 
ADA in the treatment of moderately to severely active ulcerative colitis, 
independently of patient subgroup.  
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OBJECTIVES: To demonstrate the efficacy, security and effectiveness of tenofovir 
disoproxil fumarate (Viread®) in the treatment of patients with chronic hepatitis 
B (CHB) in Mexico, from the Mexican institutional perspective. METHODS: We 
used decision analysis to calculate the cost-effectiveness of 5 competing 
strategies in CHB treatment, 1) tenofovir DF; 2) Entecavir; 3) Adefovir; 4) 
Lamivudine; and 5) Peginterferon alfa-2a, from the insititutional perspective. A 
Markov model was developed over 40 years’ time horizon. The outcome measure 
was the life years gained (LY). Direct health care cost where used and the 
discount rate was of 5% for cost and life years, also incremental cost 
effectiveness ratio (ICER), sensitivity analyses and probabilistic sensitivity 
analyses were performed. RESULTS: Tenofovir DF had more effectiveness and 
less cost in the treatment of CHB; in the Markov model tenofovir DF had the 
highest life years gained compared with all other therapies under evaluation. 
Tenofovir DF had 15.49LY with a cost of $363,314.84, Entecavir had 15.37LF with a 
cost of $435,849.99, Adefovir had 14.89LY with a cost of $487,457.55, Lamivudina 
had 13.84LY with a cost of $498,603.87 and Peginterferon alfa-2a had 13.56LY with 
a cost of $406,795.25, hence all the therapies had an ICER dominated by tenofovir 
DF in all the scenarios. The sensitivity analyses proved that tenofovir DF was 
cost effective compared to all other therapies under evaluation in the treatment 
of CHB patients in Mexico. According to the probabilistic sensitivity analyses, the 
likelihood of tenofovir DF to be cost effective is 88% under the willingness-to-pay 
threshold in Mexico. CONCLUSIONS: There is evidence from the clinical and the 
cost effectiveness study that the use of tenofovir DF in the treatment of patients 
with CHB is cost effective, and must be considered as first option in the 
treatment of patients with CHB diagnosis in Mexico.  
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OBJECTIVES: In observational studies and randomized trials of patients with 
hepatitis C infection, higher medication adherence is associated with improved 
clinical outcomes. We evaluated the impact of adherence on long-term outcomes 
and costs in patients with genotype 1 chronic hepatitis C (CHC) receiving 
peginterferon and ribavirin (PEG-RBV). METHODS: We utilized a cohort Markov 
model describing the natural history of hepatitis C infection in a population of 50 
year-old, treatment-experienced subjects to evaluate transitions between CHC, 
compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, liver 
transplant, liver transplant survivor, and death. Using previously published data 
from the Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial, we 
modeled four levels of medication adherence: >80% PEG-RBV, >80% PEG/<80% 
RBV, <80% PEG/>80% RBV, and <80% PEG-RBV. We calculated the difference in 
total liver-related health care costs between patients in the lowest versus each 
higher level of adherence following a hypothetical nursing-based intervention 
program, and performed probabilistic sensitivity analysis to evaluate uncertainty 
in our results. RESULTS: Over a lifetime horizon, comparing patients of highest 
versus lowest adherence levels, we found the following reductions in liver-
related events: 9.9% compensated cirrhosis, 4.7% decompensated cirrhosis, 1.4% 
hepatocellular carcinoma, and 0.5% liver transplant. Among the various 
scenarios of medication adherence, the difference in total discounted treatment 
and medication costs ranged from $12,820 to $62,690. Thus, an intervention that 
could, on average, improve adherence by 20% would lead to cost offsets of $29, 
850 and improvement in QALYs of 0.378. The 95% confidence ranges from 
probabilistic sensitivity analysis were $18,790-$35,600 and -0.387 to 0.810 QALYs. 
CONCLUSIONS: This model-based analysis demonstrates that increased patient 
adherence may result in improved outcomes and reduced costs. Future research 
should focus on the design of targeted interventions to implement these 
findings.  
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OBJECTIVES: To demonstrate the efficacy, security and effectiveness of 
alverine/simethicone (Meteospasmyl®) in the treatment of patients with irritable 
bowel syndrome (IBS) in Mexico, from institutional perspective. METHODS: We 
used decision analysis to calculate the cost-effectiveness of 3 competing 
strategies in IBS treatment, 1) alverine/simethicone (A/S); 2) pinaverium bromide 
(PB); and 3) tegaserod (T). A decision tree was developed over 1 month time 
horizon, and then a Markov model was designed over 13 months, this model was 
carry out in two scenarios, the first Markov model studies the patient treatment 
only with one drug therapy, the second one analyses the patient using a switch 
of treatment if the patient didn’t respond to the first option. The outcome 
measure was the global improvement of the symptoms and the time without the 
disease respectively. Direct health care cost where used, also incremental cost 
effectiveness ratio (ICER), sensitivity analyses and probabilistic sensitivity 
analyses was performed. RESULTS: A/S had more effectiveness and less cost in 
the treatment of IBS; in the decision tree, for every 1% of patients with clinical 
response using A/S, it must be pay an average of $3048.15, in the Markov model 
A/S compared to PB was a dominant strategy; T was extended dominated in both 
analyses from the institutional perspective. The sensitivity analyses proved that 
A/S was cost effective compared to PB and T in the treatment of IBS patients in 
Mexico. According to the probabilistic sensitivity analyses, the likelihood of A/S 
to be cost effective is 90% under the willingness-to-pay threshold in Mexico. 
CONCLUSIONS: There is evidence from the clinical and the cost effectiveness 
study that the use of A/S in the treatment of patients with IBS is cost effective, 
and must be considered as first option in the treatment of patients with IBS 
diagnosis in Mexico.  
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OBJECTIVES: Recent advances in diagnostic imaging technology have been 
followed by an increased incidence of asymptomatic pancreatic neoplasms. 
Recommended clinical approaches to continued monitoring vary in frequency, 
invasiveness and cost. This study's objective is to compare the risks and cost 
implications associated with annual computed tomography (CT), empiricism 
(watchful waiting), endoscopic ultrasound (EUS) and magnetic resonance 
imaging (MRI) screening. METHODS: Cost and accuracy information was 
obtained from published peer-reviewed journal articles. Empiricism serves as a 
baseline comparison of these procedures and includes the cost of one annual 
physician visit. Incremental Cost Effectiveness Ratios (ICERs) were calculated, 
(procedure cost/detection rate accuracy) and compared across diagnostic testing 
procedures. Risk was defined as the chance of missed detection due to less 
accurate imaging or lack of screening. RESULTS: Costs for empiricism ($82) were 
minimal when compared to CT ($196), EUS ($671) and MRI ($363). Although 
empiricism was the least expensive monitoring strategy, it was associated with 
the highest risk of undetected metastasizings. Of the diagnostic options, CT had 
